Project Grant R01AI189439

Award Date 6/20/25
Completion Date 5/31/30
Dollars Obligated $383K
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Louisiana, USA
Similar Awards
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to investigate the mechanistic impact of a genetic variant associated with Parkinson's disease on immune system function and susceptibility to infection. The $162,000 award to The Administrators of Tulane Educational Fund (Tulane University) will fund experiments to uncover how the LRRK2-G2019S mutation...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $162,000 in funding to The Washington University to conduct research on the role of plasmacytoid dendritic cells (pDCs) in Mycobacterium tuberculosis (MTB) infection. The goal is to characterize pDC function during MTB infection to identify potential pDC-specific therapeutic targets that could lead to host-directed...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $643,718 to the University of California, Los Angeles (UCLA) from January 1, 2025 to December 31, 2029. The objective of this award is to study the role of interferon-regulatory factors (IRFs) and signal transducers and activators of transcription (STATs) in regulating the epigenome and gene expression of...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $185,280 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Texas A&M University System Health Science Center to study how the Mycobacterium tuberculosis (MTB) secreted protein Rv1075c hijacks host histone methyltransferases to promote infection. The key objectives are to define how histone methylation changes at innate immune genes during MTB infection, and investigate how...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $456,000 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to the University of Texas Medical Branch at Galveston (UTMB) to investigate how regulatory mechanisms shape the interleukin-6 (IL-6) immune response during respiratory viral infections. The two-year grant (July 2024 - June 2026) aims to understand how changes in a cis-regulatory element control IL-6 expression in mucosal epithelial cells,...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant valued at $718,758 to the Texas Biomedical Research Institute under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant is focused on evaluating the use of IL-21-IgFc fusion protein as a host-directed immunotherapy to improve immune reconstitution and reduce the risk of latent tuberculosis (TB) reactivation in Mycobacterium tuberculosis (MTB) and simian immunodeficiency virus (SIV)...
This $150,921 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to understand how the interplay between membrane rafts and protein condensates regulates T cell signaling and activation. The goal is to characterize the biophysical properties of membranes coupled to the LAT protein condensates, and evaluate the effects of membrane lipid remodeling on LAT...
This federal Project Grant award of $637,275 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to uncover the mechanisms by which bacterial pathogens rapidly develop tolerance to chemical stressors, such as antibiotics. The research aims to define novel stress tolerance mechanisms in pathogens, with implications for improving antibacterial therapies and public health. Key focus areas...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $453,429 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to Texas A&M AgriLife Research to investigate the regulation of RNA editing in two life cycle stages of Trypanosoma brucei, a pathogenic kinetoplastid protozoa. The research aims to provide insights into the key proteins and mechanisms involved in differential RNA editing across the T. brucei life cycle, which alternates between mammalian...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $239,120 to Tufts University School of Medicine to analyze the heterogeneity of cell death responses in influenza virus-infected cells. The research aims to understand the interplay between transcriptional programs and different forms of cell death during viral infection, with the goal of elucidating which cell death...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $382,500.00 to study the role of the protein TXLNA in innate immune responses to cytosolic DNA. The research aims to determine how TXLNA regulates the STING-mediated activation of TBK1, a key signaling pathway involved in the production of type I interferons in response to cytosolic DNA. The project will employ a knockout mouse model and molecular biology techniques to elucidate the regulatory mechanisms governing this pathway, with the goal of informing the development of therapeutic strategies for infectious diseases and autoimmune disorders. The award period runs from June 20, 2025 to May 31, 2030 and is being conducted by Tulane University, a private non-profit research institution.

Generated 7/15/25, 11:39 AM